Drug Addiction and Chronic Pain: A Review of Animal Models

  • Carrie L. Wade
  • George F. Koob
  • Leandro F. Vendruscolo
Chapter
Part of the Contemporary Clinical Neuroscience book series (CCNE, volume 17)

Abstract

Animal models of pain play an important role in the characterization and development of therapeutics for several pain conditions. Models that mimic the development and maintenance of chronic pain conditions are especially important and have directly impacted the availability of treatments for many common pain conditions such as neuropathic, inflammatory, and visceral. The most efficacious and first choice treatment option for chronic pain is opioid analgesics. Besides being potent analgesics, opioids produce an intense pleasant feeling (reward), especially in individuals not suffering actual pain. This raises the concern that the chronic treatment of pain with opioids can cause opioid tolerance and dependence. This chapter discusses the animal models that are used to quantitatively measure nociception and analgesia, and animal models that are used to study inflammatory, neuropathic, and visceral pain. Additionally, we discuss the animal models used to study opioid dependence.

Keywords

Morphine Cocaine Paclitaxel Fentanyl Indomethacin 

References

  1. 1.
    Weinstein SM, Laux LF, Thornby JI, Lorimor RJ, Hill Jr CS, Thorpe DM, Merrill JM. Physicians’ attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J. 2000;93:479–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Weinstein SM, Laux LF, Thornby JI, Lorimor RJ, Hill Jr CS, Thorpe DM, Merrill JM. Medical students’ attitudes toward pain and the use of opioid analgesics: implications for changing medical school curriculum. South Med J. 2000;93:472–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Blyth FM, March LM, Nicholas MK, Cousins MJ. Chronic pain, work performance and litigation. Pain. 2003;103:41–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. Rheumatology (Oxford). 2008;47:670–8.CrossRefGoogle Scholar
  5. 5.
    Scascighini L, Sprott H. Chronic nonmalignant pain: a challenge for patients and clinicians. Nat Clin Pract Rheumatol. 2008;4:74–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Lynch ME, Campbell F, Clark AJ, Dunbar MJ, Goldstein D, Peng P, Stinson J, Tupper H. A systematic review of the effect of waiting for treatment for chronic pain. Pain. 2008;136:97–116.PubMedCrossRefGoogle Scholar
  7. 7.
    Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain. 1999;Suppl 6:S141–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Chapman CR, Hill HF. Prolonged morphine self-administration and addiction liability. Evaluation of two theories in a bone marrow transplant unit. Cancer. 1989;63:1636–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer. 2003;11:84–92.PubMedGoogle Scholar
  10. 10.
    Gilson AM, Joranson DE. Controlled substances and pain management: changes in knowledge and attitudes of state medical regulators. J Pain Symptom Manage. 2001;21:227–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Davis MP. Guidelines for breakthrough pain dosing. Am J Hosp Palliat Care. 2003;20:334.PubMedCrossRefGoogle Scholar
  12. 12.
    Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Erichsen HK, Hao JX, Xu XJ, Blackburn-Munro G. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. Pain. 2005;116:347–58.PubMedCrossRefGoogle Scholar
  14. 14.
    LaBuda CJ, Little PJ. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J Neurosci Methods. 2005;144:175–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Wu HE, Schwasinger ET, Hong JS, Tseng LF. Pretreatment with antiserum against dynorphin, substance P, or cholecystokinin enhances the morphine-produced anti-allodynia in the sciatic nerve ligated mice. Neurosci Lett. 2005;386:46–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Kirsh KL, Whitcomb LA, Donaghy K, Passik SD. Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study. Clin J Pain. 2002;18:S52–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA. 2005;293:3043–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Foley KM. Opioids and chronic neuropathic pain. N Engl J Med. 2003;348:1279–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, Simonnet G. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology. 2000;92:465–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32:77–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O’Reilly T, Wotherspoon G, Winter J, Green J, Urban L. A rat model of bone cancer pain. Pain. 2002;96:129–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Kocher L, Anton F, Reeh PW, Handwerker HO. The effect of carrageenan-induced inflammation on the sensitivity of unmyelinated skin nociceptors in the rat. Pain. 1987;29:363–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Bellavance LL, Beitz AJ. Altered c-fos expression in the parabrachial nucleus in a rodent model of CFA-induced peripheral inflammation. J Comp Neurol. 1996;366:431–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Colpaert FC, De Witte P, Maroli AN, Awouters F, Niemegeers CJ, Janssen PA. Self-administration of the analgesic suprofen in arthritic rats: evidence of Mycobacterium butyricum-induced arthritis as an experimental model of chronic pain. Life Sci. 1980;27:921–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Colpaert FC. Evidence that adjuvant arthritis in the rat is associated with chronic pain. Pain. 1987;28:201–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Kim KJ, Yoon YW, Chung JM. Comparison of three rodent neuropathic pain models. Exp Brain Res. 1997;113:200–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992;50:355–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain. 1999;80:67–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain. 2000;87:149–58.PubMedCrossRefGoogle Scholar
  32. 32.
    Gottschalk PG, Dyck PJ, Kiely JM. Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology. 1968;18:875–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 1996;73:259–65.PubMedCrossRefGoogle Scholar
  34. 34.
    Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. Vincristine-induced allodynia in the rat. Pain. 2001;93:69–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain. 2007;128:225–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001;94:293–304.PubMedCrossRefGoogle Scholar
  37. 37.
    Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse. 1987;13:1–17.PubMedCrossRefGoogle Scholar
  38. 38.
    Cami J, de Torres S, San L, Sole A, Guerra D, Ugena B. Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clin Pharmacol Ther. 1985;38:336–41.PubMedCrossRefGoogle Scholar
  39. 39.
    APA. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: APA; 2000.Google Scholar
  40. 40.
    Caine S, Lintz, R., Koob GF. Intravenous drug self-administration techniques in animals. Behavioral Neuroscience: A Practical Approach. 1993;117–43.Google Scholar
  41. 41.
    Stafford D, LeSage MG, Glowa JR. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology (Berl). 1998;139:169–84.CrossRefGoogle Scholar
  42. 42.
    Hodos W. Progressive ratio as a measure of reward strength. Science. 1961;134:943–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Vendruscolo LF, Schlosburg JE, Misra KK, Chen SA, Greenwell TN, Koob GF. Escalation patterns of varying periods of heroin access. Pharmacol Biochem Behav. 2011;98(4):570–4.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, Martin TJ. Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci. 2000;20:4555–62.PubMedGoogle Scholar
  45. 45.
    McNamara R, Dalley JW, Robbins TW, Everitt BJ, Belin D. Trait-like impulsivity does not predict escalation of heroin self-administration in the rat. Psychopharmacology (Berl). 2010;212:453–64.CrossRefGoogle Scholar
  46. 46.
    Lenoir M, Ahmed SH. Supply of a nondrug substitute reduces escalated heroin consumption. Neuropsychopharmacology. 2008;33:2272–82.PubMedCrossRefGoogle Scholar
  47. 47.
    Chen SA, O’Dell LE, Hoefer ME, Greenwell TN, Zorrilla EP, Koob GF. Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology. 2006;31:2692–707.PubMedCrossRefGoogle Scholar
  48. 48.
    Ahmed SH, Walker JR, Koob GF. Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology. 2000;22:413–21.PubMedCrossRefGoogle Scholar
  49. 49.
    Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: change in hedonic set point. Science. 1998;282:298–300.PubMedCrossRefGoogle Scholar
  50. 50.
    Walker JR, Chen SA, Moffitt H, Inturrisi CE, Koob GF. Chronic opioid exposure produces increased heroin self-administration in rats. Pharmacol Biochem Behav. 2003;75:349–54.PubMedCrossRefGoogle Scholar
  51. 51.
    Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF. Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci. 2006;26:5894–900.PubMedCrossRefGoogle Scholar
  52. 52.
    Sherman JE, Zinser MC, Sideroff SI, Baker TB. Subjective dimensions of heroin urges: influence of heroin-related and affectively negative stimuli. Addict Behav. 1989;14:611–23.PubMedCrossRefGoogle Scholar
  53. 53.
    Koob GF. Brain stress systems in the amygdala and addiction. Brain Res. 2009;1293:61–75.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Deneau G, Yanagita T, Seevers MH. Self-administration of psychoactive substances by the monkey. Psychopharmacologia. 1969;16:30–48.PubMedCrossRefGoogle Scholar
  55. 55.
    Negus SS. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone. J Pharmacol Exp Ther. 2006;317:711–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Barbier E, Vendruscolo LF, Schlosburg JE, Edwards S, Juergens N, Park PE, Misra KK, Cheng K, Rice KC, Schank J, Schulteis G, Koob GF, Heilig M. The NK1 receptor antagonist L822429 reduces heroin reinforcement. Neuropsychopharmacology. 2013;38(6):976–84.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Shalev U, Highfield D, Yap J, Shaham Y. Stress and relapse to drug seeking in rats: studies on the generality of the effect. Psychopharmacology (Berl). 2000;150:337–46.CrossRefGoogle Scholar
  58. 58.
    Crombag HS, Bossert JM, Koya E, Shaham Y. Context-induced relapse to drug seeking: a review. Philos Trans R Soc Lond B Biol Sci. 2008;363:3233–43.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Stewart J. Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci. 2000;25:125–36.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Shaham Y, Erb S, Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev. 2000;33:13–33.PubMedCrossRefGoogle Scholar
  61. 61.
    Sanchis-Segura C, Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol. 2006;11:2–38.PubMedCrossRefGoogle Scholar
  62. 62.
    Stinus L, Caille S, Koob GF. Opiate withdrawal-induced place aversion lasts for up to 16 weeks. Psychopharmacology (Berl). 2000;149:115–20.CrossRefGoogle Scholar
  63. 63.
    Frenois F, Cador M, Caille S, Stinus L, Le Moine C. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci. 2002;16:1377–89.PubMedCrossRefGoogle Scholar
  64. 64.
    Gellert VF, Holtzman SG. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther. 1978;205:536–46.PubMedGoogle Scholar
  65. 65.
    Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl). 2010;210:121–35.CrossRefGoogle Scholar
  66. 66.
    Schulteis G, Heyser CJ, Koob GF. Differential expression of response-disruptive and somatic indices of opiate withdrawal during the initiation and development of opiate dependence. Behav Pharmacol. 1999;10:235–42.PubMedCrossRefGoogle Scholar
  67. 67.
    Edwards S, Vendruscolo LF, Schlosburg JE, Misra KK, Wee S, Park PE, Schulteis G, Koob GF. Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF(1) receptor antagonism. Neuropharmacology. 2012;62:1142–51.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Campbell UC, Carroll ME. Acquisition of drug self-administration: environmental and pharmacological interventions. Exp Clin Psychopharmacol. 2000;8:312–25.PubMedCrossRefGoogle Scholar
  69. 69.
    Panlilio LV, Goldberg SR. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction. 2007;102:1863–70.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Bergman J, Paronis CA. Measuring the reinforcing strength of abused drugs. Mol Interv. 2006;6:273–83.PubMedCrossRefGoogle Scholar
  71. 71.
    Martin TJ, Kim SA, Buechler NL, Porreca F, Eisenach JC. Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology. 2007;106:312–22.PubMedCrossRefGoogle Scholar
  72. 72.
    Martin TJ, Ewan E. Chronic pain alters drug self-administration: implications for addiction and pain mechanisms. Exp Clin Psychopharmacol. 2008;16:357–66.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Lyness WH, Smith FL, Heavner JE, Iacono CU, Garvin RD. Morphine self-administration in the rat during adjuvant-induced arthritis. Life Sci. 1989;45:2217–24.PubMedCrossRefGoogle Scholar
  74. 74.
    Colpaert FC, Tarayre JP, Alliaga M, Bruins Slot LA, Attal N, Koek W. Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats. Pain. 2001;91:33–45.PubMedCrossRefGoogle Scholar
  75. 75.
    Backonja MM, Gosnell BA. Analgesia and oral opioid consumption: strengths and shortcomings of methods. Pain. 1996;64:398–401.PubMedCrossRefGoogle Scholar
  76. 76.
    Kupers R, Gybels J. The consumption of fentanyl is increased in rats with nociceptive but not with neuropathic pain. Pain. 1995;60:137–41.PubMedCrossRefGoogle Scholar
  77. 77.
    Fields HL. The doctor’s dilemma: opiate analgesics and chronic pain. Neuron. 2011;69:591–4.PubMedCentralPubMedCrossRefGoogle Scholar
  78. 78.
    Edlund MJ. Chronic opioid therapy for chronic noncancer pain in the United States: long day’s journey into night? Gen Hosp Psychiatry. 2011;33:416–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007;129:235–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Carrie L. Wade
    • 1
  • George F. Koob
    • 1
  • Leandro F. Vendruscolo
    • 1
  1. 1.Committee on the Neurobiology of Addictive Disorders, The Scripps Research InstituteLa JollaUSA

Personalised recommendations